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ABSTRACT 
In 2011, a field trial was conducted in southeastern West Virginia to evaluate the safety and 
immunogenicity of a live recombinant human adenovirus (serotype 5)-rabies glycoprotein 
vaccine (ONRAB®) in wild raccoons and skunks. ONRAB® was selected for evaluation based on 
the success achieved in eliminating raccoon rabies from Ontario and Quebec, Canada, through 
the integration of this vaccine into rabies management strategies and significantly higher sero-
positivity in comparison to Raboral V-RG® in studies along the U.S.-Canada border. The field 
trial site was composed of forested and agricultural habitats in an area where raccoon rabies is 
enzootic and oral rabies vaccine (ORV) has never been used as a management strategy. The 
ULTRALITE bait is composed of a small blister pack that contains the ONRAB® vaccine with a 
waxy coating matrix of sweet attractants, impregnated with tetracycline biomarker, camouflaged 
by a khaki green dye. Approximately 80,000 baits were distributed at 75 baits/km2 mostly by 
fixed wing aircraft along parallel flight lines spaced at 750 m intervals. There were no phone 
calls related to human or pet bait contacts reported through the affixed, legible toll free phone 
number on each bait. Relatively low human population density in the study area and bait 
attributes that may make them less attractive to dogs could have been contributing factors 
resulting in no reported bait contacts. Histopathology results from up to 23 tissue types from 
diverse target and nontarget wildlife species samples pre (n=290) and post-ORV (n=300) with 
ONRAB® will be provided under a separate cover once the analysis is completed. No differences 
were observed between control and treatment captive animals, including cottontail rabbit 
(Sylvilagus floridanus), opossum (Didelphis virginiana), fox squirrel (Sciurus niger), and eastern 
wild turkey (Meleagris gallopavo silvestri) that received a 10x ONRAB® dose in a companion 
histopathology study conducted at the Wildlife Services (WS), National Wildlife Research 
Center. These species that have not been previously evaluated for potential ONRAB® effects are 
common to the West Virginia field trial site.  The proportion of raccoons categorized as sero-
positive was significantly higher in (P< 0.05) the post-ORV ONRAB® baiting period (49.4%, 
n=296) in comparison to the pre-ORV (9.6%, n=395)) period (naïve to ORV either with 
ONRAB® or Raboral V-RG® but where raccoon rabies is enzootic).  The 49.4% sero-positivity in 
raccoons was the highest observed by WS for areas with similar management histories that were 
baited once at 75 baits/km2 with Raboral V-RG®.  Biomarker presence was significantly 
(P<0.05) higher among sero-positive raccoons post-ORV and similar (P>0.05) among raccoons 
during the pre-ORV period, an indication of vaccine-induced rabies virus neutralizing antibodies 
(RVNA) following bait consumption. Skunk sample size was inadequate to assess ONRAB® 
effects, but other studies have not shown a strong RVNA response at 75 baits/km2. Overall, the 
safety and immunogenicity outcomes from this field trial support replicating the West Virginia 
field trial to determine if raccoon population immunity would increase as a function of a second 
annual ORV campaign with ONRAB®. Expansion of field trials into other strategic areas such as 
the Ohio contingency action zone, the Niagara Frontier and along the Quebec border with New 
York, Vermont and New Hampshire is recommended. 
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INTRODUCTION 
In 2011, APHIS, Wildlife Services (WS) coordinated a collaborative oral rabies vaccine field 
trial to evaluate the safety and immunogenicity of ONRAB® (Artemis Technologies, Guelph, 
Ontario, Canada) in raccoons and skunks in West Virginia (Appendix A).  It was the first field 
trial of this type in the U.S. in over 20 years (Roscoe et al. 1998). This field trial was conducted 
to evaluate a vaccine that has the potential to be licensed and applied strategically to more 
aggressively meet raccoon rabies management goals, including elimination.  ONRAB® is a live 
recombinant vaccine that uses human adenovirus (serotype 5) to express the rabies virus 
glycoprotein gene (Charlton et al., 1992).  Over 6 million doses of ONRAB® have been 
distributed in Ontario since 2006 for skunk and raccoon rabies control (D. Donovan, personal 
communication) and Quebec since 2007 for raccoon rabies control (J. Mainguy, personal 
communication).  Both Provinces appear to have eliminated raccoon rabies virus variant through 
the integration of ONRAB® into broader rabies control strategies (Rosatte et al. 2009a, Rees et 
al. 2011). 
Highly collaborative processes were put in place to meet regulatory, technical, environmental 
and logistical demands associated with the vaccine-bait field trial conducted in West Virginia. 
Collaborators included county, state, federal and international partners from government and 
non-government organizations, as well as Artemis Technologies, ONRAB® manufacturer (Table 
1).  Artemis Technologies was responsible for providing the requisite data to APHIS, Veterinary 
Services, Center for Veterinary Biologics (CVB), with formal public health input from CDC to 
facilitate a comprehensive ONRAB® risk assessment. Published information on ONRAB® and 
data on file were also part of the foundation for a WS Environmental Assessment that evaluated 
the potential impacts of releasing this vaccine into the wild in West Virginia.  A joint CVB and 
WS Federal Register Notice was issued to notify the public of plans for an ONRAB® field trial 
and to solicit input and comments (U. S. Department of Agriculture, 2011a). 
This report covers key aspects and findings of the ONRAB® field trial and provides 
recommendations for future field evaluations. 
BRIEF BACKGROUND 
The concept of oral rabies vaccination (ORV) to control rabies in free-ranging wildlife originated 
in the U.S. (Baer et al., 1971; Baer, 1988).  ORV has been widely used in Europe beginning in 
the late 1970’s and Canada in the late 1980’s with success in controlling and eliminating rabies 
in foxes from several European countries (Blancou, 2008; Wandeler, 2008) and all but a few 
residual foci of an arctic variant of rabies in skunks in Ontario (Nadin-Davis et al., 2006; Rosatte 
et al., 2011), as well as raccoon rabies from Ontario (Rosatte et al., 2009b) and Quebec (Rees et 
al., 2011)(no cases since 2009). The rapid spread of raccoon rabies along the eastern seaboard of 
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the U.S. and west to eastern Ohio as the probable result of translocations from Florida to Virginia 
and West Virginia during the 1970’s (Nettles et al., 1979) served as a major stimulus for 
intervention with ORV to prevent raccoon rabies from gaining an even broader geographic 
footprint in the U.S. 
Due to the risk, albeit it low, of vaccine-induced rabies associated with residual pathogenicity in 
the Evelyn Rockitnicki Abelseth (ERA) strain of attenuated rabies virus (Fehlner-Gradiner et al., 
2008), a live recombinant Vaccinia-rabies glycoprotein (V-RG) vaccine became the prime 
candidate for testing in the U.S. (Rupprecht et al., 1986). This vaccine cannot cause rabies, 
although low levels of risk may be associated with exposure to the virus vector (Roess et al., 
2012). However, V-RG proved to be safe in more than 50 vertebrate species (Artois et al., 1990; 
Rupprecht et al., 1992a; Rupprecht et al., 1992b). As a result of field safety and immunogenicity 
testing in the early 1990s (Hanlon et al., 1998; Hanlon and Rupprecht, 1998; Roscoe et al., 
1998), V-RG was conditionally licensed in 1995, and fully licensed in1997, in the U.S. for 
vaccination of free-ranging raccoons by Merial Ltd., Athens, Georgia under the registered name 
Raboral V-RG®.  It was also fully licensed in 2002 for coyotes in the U.S. and for raccoons in 
Canada (Rosatte et al., 2001). It has been approved for experimental use in wild gray foxes and 
has been used for this purpose in Arizona, New Mexico, and Texas (J. Maki, personal 
communication). Raboral V-RG® currently remains the only licensed oral rabies vaccine for use 
in the U.S. 
Following the first field trial with V-RG in 1990, the number of vaccine-laden baits distributed 
annually in the U.S. rose exponentially through 2006, but has decreased to about 8 million baits 
in 2011 due to implementation of efficiencies such as consistency in ORV zone width throughout 
most areas and 750m flight line spacing, as well as level WS funding for rabies management 
(Figure 1). Since WS involvement in rabies management, APHIS has contributed about 120 
million Raboral V-RG® baits for distribution in the U.S. between 1995 and 2010 (U.S. 
Department of Agriculture, 2012). More than 75% of those baits have been used in campaigns to 
prevent the spread of raccoon rabies beyond the eastern U.S. (Figure 2) and the remainder has 
been applied in Texas, New Mexico and Arizona for rabies control and elimination efforts in 
coyotes and gray foxes (U.S. Department of Agriculture, 2008; U.S. Department of Agriculture, 
2009; U.S. Department of Agriculture, 2010a). 
Coordinated ORV with Raboral V-RG® has resulted in three major rabies management 
accomplishments in the U.S. Canine rabies from sources in Mexico, which had spilled over and 
spread among coyotes in south Texas, has been eliminated through the integration of ORV into 
conventional rabies prevention and control programs (Fearneyhough et al., 1998; Sidwa et al., 
2005).  This success led to the U.S. being declared canine rabies free in 2008 (Velasco-Villa et 
al., 2008). ORV has also been successfully applied to control a unique variant of gray fox rabies 
in western Texas, with no reported cases since May 2009 (Blanton et al., 2011).  Intervention 
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with ORV beginning in 1997 has also prevented appreciable spread of raccoon rabies from its 
new-found stronghold in the eastern U.S. (Slate et al., 2009). 
These accomplishments are noteworthy, yet the inability to eliminate raccoon rabies in high risk 
spread corridors has prompted the need to evaluate vaccines that may be capable of producing 
higher levels of population immunity to achieve this programmatic goal. Ideally, vaccines 
deemed safe, inexpensive and immunogenic in all meso-carnivore rabies reservoir species under 
field conditions are desired. To date, little RVNA response has been observed among skunks 
captured from ORV zones established with Raboral V-RG® to raccoon rabies control (Slate et al., 
2009).  WS and collaborators identified the need to test new vaccine-baits as a priority in the 
Vaccine/ Bait/Biomarker Team as part of discussions at the annual WS National Rabies 
Management Team meeting during the past decade.  In addition, a comprehensive review of the 
WS, National Rabies Management Program recommended that new or improved vaccine-baits 
be brought on line as swiftly as possible to better ensure program sustainability and success (U.S. 
Department of Agriculture, 2010b). 
After considering four candidate vaccines (Table 2), WS and collaborators decided to pursue a 
field trial with ONRAB® in 2011. That decision was largely based on extensive use of ONRAB® 
in Ontario and Quebec along the U.S border without untoward events and success in reducing 
and eliminating raccoon rabies. Other contributing factors included the inability to access other 
candidate vaccines for field testing in a timely fashion.  Also, no skunks infected with the 
raccoon rabies virus variant have emerged in Ontario since 2004, or Quebec since 2009, 
suggesting that the occurrence of skunks infected with raccoon rabies is dependent on spillover 
from the raccoon reservoir.  In addition, under operational rabies control strategies using  high 
ORV bait densities (300 baits/km2) and narrow flight lines (250m), meaningful levels of 
immunity have been achieved in skunk populations in an attempt to eliminate residual foci of an 
arctic rabies variant from Ontario (Rosatte et al., 2011). While these bait densities would not be 
sustainable at the landscape level, perhaps bait modifications could enhance future performance 
of ONRAB® in skunks at lower bait densities.    
ONRAB® uses a human adenovirus type 5 (HAd5) as a vector to express the rabies virus 
glycoprotein gene.  The virus vector has a well-characterized molecular structure, genomic 
stability, and possesses the ability to grow high titers in a wide spectrum of cells (Graham and 
Prevec, 1992). Each ONRAB® bait contains 1.8 ±0.1 ml of HAd5 ONRAB® vaccine (titer of not 
<109.5 cell culture infectious dose 50%[CCID50]/ml) in an elongated plastic blister pack coated 
with an attractant-bait matrix (Figure 3).The matrix is composed of partially hydrogenated 
vegetable shortening (34%), Microbond® wax (International Wax Ltd., Agincourt, Ontario, 
Canada) (30%), stearine (12.5%), icingsugar (20%), vegetable oil (1%), artificial marshmallow 
flavor (1%), artificial sweet flavor (1%), and a fat-soluble food dye (0.5% khaki green) to 
camouflage the baits. Each vaccine-bait weighs approximately 4 g. The body of the blister pack 
is an elongated oval with dimensions of 1.81 x 0.55 x 0.39 in (30 x 14 x 10 mm) and a 
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rectangular lip extending to 1.57 x 0.79 in (40x20 mm) (Figure 3). The blister pack contains an 
identifying label as to the contents of the bait and a toll-free phone number where people can 
obtain information about the baits (Rosatte et al., 2009a).  
The ONRAB® bait matrix also can deliver 100 mg of tetracycline hydrochloride as a biomarker 
to aid in evaluating bait ingestion. Tetracycline deposits in metabolically active portions of bones 
and teeth of animals, which can be viewed in slide preparations under fluorescent light 
microscopy. Tetracycline-positive tooth or bone indicates the likelihood that an animal has eaten 
at least one bait (Johnston and Voight, 1982; Rupprecht et al., 1987; Rosatte et al., 2009a). The 
presence of tetracycline does not equate to immunity because it is possible for an animal to eat 
the outer bait matrix without rupturing the blister pack, resulting in no oral exposure to the 
vaccine.  Potential sources of "background" tetracycline may include consumption of medicated 
feeds such as those sometimes used for production animals, intentional treatment by humans 
with tetracycline, and non-specific fluorescence that may be found naturally (Chopra and 
Roberts, 2001). 
FIELD TRIAL DESIGN 
The ONRAB® ORV zone was 1,460 km2 composed of hardwood and mixed coniferous-
hardwood forest, interspersed with livestock agriculture and small towns (U.S. Department of 
Agriculture, 2011a). The spatial field trial design contained four 127 km2 sampling cells, 
separated from each other by a 5 km buffer (Figure 2).  The distance from the western edge of 
the ONRAB® sampling cells to the existing ORV zone baited at 75 baits/km2 since 2001 (U.S. 
Department of Agriculture 2005) with Raboral V-RG® was 11km. The buffer was provided to 
reduce the chance of confounded serological results. The distance from the edges of the sampling 
cells and the outer perimeter of ONRAB® baited area was 5 km to reduce dilution effect from 
raccoon home ranges that may overlap from ONRAB® naive areas, where raccoons and skunks 
would not have had equal opportunity to consume baits as compared to animals with home 
ranges totally within the ONRAB® zone. A total of 79,027 ONRAB® baits with tetracycline 
biomarker in the bait matrix were distributed within the field trial zone, with 77,448 baits aerially 
distributed along parallel flight lines at a 750 m spacing.  A total of 1,580 ONRAB® baits were 
distributed through ground baiting in the vicinity of towns in the field trial zone where aerial 
baiting could present a safety concern. 
MATERIALS AND METHODS 
The pre and post ONRAB® sampling profile for assessing safety and immunogenicity of 
ONRAB® at 75 baits/km2 is summarized in Table 3. 
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Animal Sampling 
Target species biological and serological sampling 
Animal sampling included live (cage) trapping (Tomahawk model 608) and release of target 
species that were apparently not rabid based on behavior and gross examination for lesions. 
Suspect animals were tested for rabies using a direct rapid immunohistochemistry test (dRIT), 
with diagnostic confirmation and rabies virus variant typing performed at CDC.  Non-target 
species were either released or included among the required samples for histopathological 
analysis. The same trapping approach was applied for pre and post-ONRAB® sampling. 
About 150 live traps were set within 800 m of 25 preselected random points in each sampling 
cell to ensure adequate spatial coverage (Figure 4). The same random points were used both pre 
and post-ORV ONRAB® sampling periods, which were August 2-26, 2011 and September 21-
31, respectively. Traps were checked once every 24 hours. All rabies reservoir species captured 
during pre and post-ORV with ONRAB® were anesthetized using an IM injection of a 5:1 
mixture of ketamine and xylazine (Kreeger, 1999) so that blood as well as first premolar tooth 
samples could be collected for aging and biomarker presence, and other pertinent biological 
information such as sex, reproductive status, and the general condition of each animal. Serum 
samples were collected from blood centrifuged the same day of capture, with aliquots briefly 
stored in labeled cyrovials at minus 25-70⁰ C before shipment to the appropriate laboratory for 
analysis. After full recovery from anesthesia, all raccoons and skunks were released at their site 
of capture.  
Target species swab sampling 
The same animal capture and handling procedures were followed from day 1-6 post-ORV with 
ONRAB® to collect oral swab samples (Appendix B). However, live trapping was confined to 
the intercellular spaces between the four primary sampling cells 1-2, 2-3, and 3-4. This sampling 
scheme was used to reduce the chance of trap shyness among raccoons and skunks post-ORV 
with ONRAB® to collect blood sera and other samples, which began the recommended 5-weeks 
after bait distribution (C. Fehlner-Gardiner, personal communication) and would include 
recaptures from the pre-ORV sampling period.  Swab samples were labeled and stored in 
universal viral transport tubes (Becton Dickinson, #220222) containing 3 ml of transport medium 
and shipped in near real time to the Animal Health Diagnostic Center, Cornell University for 
analysis.   
Target and nontarget species histopathology sampling 
Victor Rat (model BM205) and mouse (model BM154) traps were used to capture small 
mammals for tissue sampling from major organs. Trapping began on July 21, 2011, two weeks 
prior to serological baselines samples, and continued opportunistically up to the distribution of 
ONRAB® baits September 16, 2011.  These samples were supplemented with live trapped 
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nontarget captures to assure a diverse representation of faunal samples for histopathological 
investigation. Larger mammals and birds were donated from WV, Division of Natural Resources 
or collected by live trapping or shooting.  
Histopathological samples were also collected from target and nontarget species within the 
ONRAB® ORV zone after the 6-day swab sampling period.  No target species were collected for 
histopathology from the four primary sampling cells within the field trial zone (Figure 2). 
Necropsies were performed on animals on the day of capture and tissues were harvested, placed 
in labeled vials in 10 percent buffered formalin, stored for a short period, and shipped for 
laboratory analysis to MD Anderson Cancer Center (Houston, Texas) according to the protocol 
in Appendix B. 
RVNA Antibody Determination 
Serum was shipped frozen in labeled, cryovials within containers of dry ice to the CDC Rabies 
Program Laboratory upon completion of the Pre-ONRAB® sampling period and again after the 
Post-ONRAB® sampling period.  The RVNA were determined at CDC using the Rapid 
Fluorescent Focus Inhibition Test (Centers for Disease Control and Prevention, 2011).  Samples 
with I.U.≥0.06 were deemed indicative of positive RVNA activity. 
Human Adenovirus (Serotype-5) Antibody Determination 
Serum was also shipped frozen in labeled, cryovials within containers of dry ice to the Animal 
Health Diagnostic Center, Cornell University to determine antibody levels of HAd5 upon 
completion of the Pre-ONRAB® sampling period and again after the Post-ONRAB® sampling 
period.  The adenovirus virus neutralization (VN) assay for Ad-5 followed standard procedures 
for VN assays in microtiter plates.  Two-fold serum dilutions (50 ul) in duplicate were mixed 
with 100-300 TCID50 of Ad-5 (VR-5 ATCC) in a 50 ul volume.  Mixtures were allowed to 
incubate for at least 1 hr at room temperature.  A 100 ul volume of indicator cells (A549 - 
ATCC) was added to each well and the plates were placed in a CO2 incubator at 37⁰C for 6 days.  
Wells were scored for the presence or absence of typical Ad-5 cytopathology.  Positive serum 
controls were an equine anti Ad-5 (CDC) and a bovine anti Ad-5 (ARS-USDA).  
Tetracycline Biomarker 
First premolars extracted from each live captured and anesthetized raccoon or skunk were 
shipped in small, labeled Manila envelopes to Matson’s Laboratory (Missoula, MT) for 
tetracycline and specific age determination based on cementum annuli counts. For the analysis in 
this report only juvenile and adult age classes could be evaluated until age specific age results 
become available. 
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ONRAB® Detection from Oral Swab Samples 
Oral swab samples were shipped in universal viral transport tubes (Becton Dickinson, #220222) 
containing 3 ml of transport medium to the Animal Health Diagnostic Center, Cornell University 
for analysis. Complete descriptions of the swab sampling protocol and the quantitative real time 
polymerase chain reaction analysis (qPCR) can be found in Appendices B and C, respectively. 
Histopathology 
Field studies 
These studies are being conducted under contract with MD Anderson Cancer Center, Houston, 
Texas. A complete description the protocol is present in Appendix B.  
Captive studies 
The study protocol for captive histopathology studies conducted at the WS, NWRC animal 
research facilities in Ft. Collins, Colorado is provided in Appendix D. The species evaluated 
included: Eastern Woodrat (Neotoma floridana), Cottontail Rabbit (Sylvilagus floridanus), 
Opossum (Didelphis virginiana), Fox Squirrel (Sciurus niger) and Eastern Wild Turkey 
(Meleagris gallopavo silvestri). Because animals in the wild could consume more than one bait, 
this study evaluated animals exposed to a 10x dose of ONRAB® and controls. 
ONRAB® Bait Contact 
Enhanced surveillance for human and domestic animal bait and vaccine contact was a critical 
component of the ONRAB® field trial to measure and address potential human and pet safety 
issues. Typically during ORV projects, reports of human or pet contact with ORV baits occurs 
when a person who has found a bait calls the toll-free number printed on the bait, or when a 
person directly contacts federal, state or local agencies after a bait is found (Roess 2012). Each 
ONRAB® bait distributed as part of this field trial contained a warning label (“Rabies vaccine, 
DO NOT TOUCH. Live adenovirus vector”) (Figure3) and was marked with a toll-free number 
that put callers in direct contact with public health officials at the West Virginia Department of 
Health and Human Services (WVDOH).  To assist the WVDOH in documenting and managing 
human bait contacts, CDC and WS developed a recommended SOP for ONRAB® bait contacts 
through a detailed algorithm (Figure 5). 
To improve surveillance for bait and vaccine contacts, a communication campaign was 
cooperatively implemented by WS specifically for the ONRAB® field trial. This campaign 
focused on raising public awareness of the field trial, enhancing public understanding of ORV 
and the associated risk of contact with baits and vaccine, and to increase reporting of potential 
vaccine exposures. 
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At the foundation of these communication efforts was the preparation and publication of a WS 
environmental assessment (EA) in cooperation with the USDA Forest Service (USFS) entitled 
"Field Trial of an Experimental Rabies Vaccine, Human Adenovirus Type 5 Vector in West 
Virginia." The EA analyzed the potential environmental effects of a proposed field trial in West 
Virginia, including portions of USFS lands but excluding Wilderness areas, to determine the 
safety and immunogenicity of the HAd5-rabies glycoprotein recombinant vaccine in raccoons 
and striped skunks. A 30-day public comment period (August 8th through September 7th, 2012) 
resulted in a total of 13 comments received from private citizens and representatives from public 
health, agriculture, and natural resources agencies in the U.S. and Canada. The majority of 
comments were supportive. Three comments were addressed, including one comment that 
expressed concern about the potential for human exposures and methods for managing these 
events, and another comment that focused on concerns that WS had not properly informed the 
residents of WV about the pending field trial. The final comment was related to a National Park 
Service request for language changes in the EA.  
WS also enhanced communication efforts through preparation and distribution of a national press 
release about the field trial. The press release was picked up by the Associated Press and widely 
distributed. In addition, at least four T.V. and newspaper interviews were conducted at a media 
event and at a Greenbrier County, WV Commission meeting, where a detailed presentation on 
the ONRAB® field trial was given to County Commissioners and the public. Finally, WS in 
collaboration with WVDOH, Ontario Ministry of Natural Resources, West Virginia Department 
of Agriculture, West Virginia University, West Virginia Division of Natural Resources and the 
USFS developed a list of talking points to assist in the coordination of key field trial messages 
provided to the public, facilitate data collection on potential bait and vaccine exposures, and 
ensure safety concerns were adequately addressed by all cooperating agencies. 
Statistical Methods 
Descriptive statistics were used to characterize the proportion of raccoons that seroconverted 
between pre- and post-baiting trapping operations. We used contingency tables and the Cochran-
Mantel-Haenszel (CMH) (Agresti, 1996) test to determine whether the proportions of individuals 
sampled in pre- and post-ORV capture efforts differed among sampling cells (1-4). The CMH 
tests were used to determine if age, sex and seroconversion status were conditionally 
independent across sampling cells. Separate CMH analyses were conducted on pre- and post-
ORV data sets. We used the McNemar test for dependent samples to determine whether the 
proportion of seroconverted individuals captured differed between the pre- and post-baiting 
sampling sessions. Finally, we conducted a factorial ANOVA to determine if recapture distance 
differed between sampling sites, and age and sex classes. 
We used Cochran-Mantel-Haenszel tests to determine whether relationships existed between bio-
marking, serology, age and sex.  Among post-ORV samples, we explored detected differences by 
multiple logistic regression.  Significance was set at P<0.05.   
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All statistical analyses were conducted in SAS 9.1 (SAS Institute, 2002) 
RESULTS AND DISCUSSION 
Target Species Serology 
Raccoons sampled during the pre-baiting trapping period displayed a 9.6 percent sero-prevalence 
for RVNA. Geographic cell-to-cell proportion of seroconverted raccoons trapped during pre-
ORV sampling did not differ relative to sex (CMH = 2.53, df = 1, p = 0.11) or age (CMH = 2.81, 
df = 1, p = 0.094) classes. The sampled cell-to-cell (Figure 4) proportion of sero-positive 
demographic classes ranged from 0-6%, and adults comprised a greater proportion of sampled 
individuals than did juveniles (Table 4). 
By contrast, 49.4 percent of raccoons sampled during the post-ORV trapping period had 
detectable RVNA. The sampled cell-to-cell proportion of sero-positive demographic classes 
ranged from 0-37% (Table 4) differed both by sex (CMH = 3.98, df = 1, p = 0.046) and age 
(CMH = 6.46, df = 1, p = 0.011) classes. These differences can be attributed to a lower 
proportion of sero-positive females in cell 1 (χ2 = 6.81, df = 1, p = 0.009), and a lower proportion 
of sero-positive juveniles in cell 4 (χ2 = 5.82, df = 1, p = 0.016). The difference in the 
proportions of individuals that were categorized as sero-positive was significantly higher 
(S=102.25, df = 1, p < 0.001) in the post-ORV with ONRAB® (49.4%) sampling period than in 
the pre- ONRAB® (9.6%) period. 
The distance between pre and post- ONRAB® recaptures differed by cell (F = 6.78, p = 0.002) 
and not by sex (F = 0.51 p = 0.48) or age class (F = 1.77, p = 0.19). The mean distance between 
recaptures was greatest for cell 2 (553 m), followed by cell 3 (260 m), cell 4 (212 m), and cell 1 
(101 m). 
Sero-positivity of 9.6 percent among raccoons (n=395) sampled prior to ONRAB® baiting 
(Table 5) in the ORV naïve raccoon rabies enzootic field trial area was higher than has been 
recorded for areas of similar status (mean=4.9%, SD=4.8, n=13) (Tables 6 and 7). Possible 
reasons for the higher baseline include naturally acquired immunity from sub-lethal exposures to 
raccoon rabies virus or movements of orally vaccinated raccoons into sampling cells from the 
adjacent Raboral V-RG® zone. However, only 3 of 31 sero-positive raccoons were also 
biomarker-positive (Table 8). In addition, the coated sachet is the primary bait type distributed in 
the adjacent Raboral V-RG®, which does not contain biomarker. Twenty-five of 310 sero-
negative raccoons were biomarker-positive from the pre-ORV sampling period (Table 8), 
suggesting that the environment may be a source of tetracycline exposure.  Raccoon rabies in this 
general area during the five years prior to the field trial (Figure 6) suggest the higher sero-
positivity in the pre-ORV sample is more likely related to naturally acquired immunity.  Previous 
studies have reported higher levels of RVNA in raccoon populations in areas naïve to the 
raccoon rabies virus variant where there have been no vaccination efforts (McLean, 1971; 
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Ramey et al., 2008). Lastly, there are no known wildlife rehabilitation facilities in the immediate 
area that may have released sufficient numbers of hand-inoculated raccoons by off-label use of 
commercial rabies vaccines to affect pre-ORV levels. Such activities are not legal in West 
Virginia.   
The 49.4 percent post-ORV with ONRAB® (uncorrected for the 9.6%) sero-positivity represents 
the highest population RVNA level WS has observed after a first baiting of a naïve area at 75 
baits/km2 where antibody baselines had been measured prior to ORV. Nine percent (3/32) were 
tetracycline and sero-positive in the pre-ONRAB® sample (Table 8), compared to 40 percent 
(48/123) post-ORV with ONRAB® (Table 9). Among pre-ORV samples, no relationships were 
detected between bio-marking, serology, age, or sex (P=0.6336).  However, among post-ORV 
samples, differences were noted relative to age (P=0.0007) predicted sero-positivity, with adults 
having >3 times higher odds of being sero-positive than juveniles (OR=3.133). Once specific age 
class data become available, biomarking will be evaluated further as younger raccoons have been 
reported to biomark with tetracycline more easily (PM1 and canine teeth only) than older 
animals (Algeo et al., in revision) due to active tooth growth (Linhart and Kennelly, 1967),  Most 
important is that tetracycline biomarking was related to serological response (P=0.0001).  
That biomarker-positives were less than RVNA-positives can be attributed in part to the use of 
the first premolar, a tissue known to be inferior to canines or mandibular bone to evaluate 
tetracycline deposition (Linhart and Kenelly, 1967; Algeo et al., in revision). The premolar was 
selected because it was more important to release raccoons and skunks to increase the probability 
of recaptures in the post-ORV sample than to euthanize animals to extract canine teeth for 
evaluation.  In spite of this, only 27 raccoons caught during post-ORV trapping were recaptured 
from the pre-ORV period.  One of 27 raccoons was RVNA-positive during pre-ORV and 8 of 27 
had evidence of RVNA post-ORV.  The single individual that had antibodies pre-ORV 
(I.U.=0.06) was also positive post-ORV with an apparent anamnestic response (I.U.=0.32).  No 
skunks were recaptured in the post-ORV period. 
While this field trial was not specifically designed to compare ONRAB® and Raboral V-RG®, a 
sero-positivity of 17.0 percent (n=11, SD 9.9%, uncorrected for RVNA of 4.9%, (n=13, SD 
4.8%) was observed after a first baiting with Raboral V-RG® in naïve areas under essentially the 
same initial ORV baiting characteristics during 2001 to 2009 in Alabama, Florida, Georgia, 
Maine, North Carolina Pennsylvania, Tennessee and Virginia and similar raccoon density indices 
(U.S. Department of Agriculture, 2011c) as in this field trial except in Florida (Tables 6 and 7). 
These results are in line with those reported by Fehlner-Gardiner et al. (2012) who found 
essentially a two-fold higher sero-positivity at 73 percent for ONRAB® in New Brunswick, 
compared to 29 percent for Raboral V-RG® across the border in Maine.  
Although comparative seroconversion samples were not collected in the adjacent Raboral V-
RG® zone in West Virginia post-ORV during 2011, in the four years previous to the ONRAB® 
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field trial, RVNA population levels ranged from 18.5 percent (n=135; 2008) to 46.4 percent 
(n=84; 2007, Table 10).  These percentages represent RVNA levels for areas that have been 
subject to annual ORV campaigns at 75 baits/km2 since 2001. 
The Raboral V-RG® zone in Virginia is the closest area for reference, at 166 km linear distance 
southwest from the ONRAB® field trial zone (Figure 7).  During 2011, a 57.1 percent (n=177) 
sero-positivity was recorded in this area, which contains similar habitats but has been baited at 
75 baits/km2since 2002. This represents a rare high RVNA, which may be partially explained by 
the presence of raccoon rabies virus variant in the area (Figure 7). While the same effect may 
apply to the field trial area (figure 6), biomarker in the ULTALITE® bait provides context for a 
vaccine-induced RVNA response.  Unfortunately, the coated sachet used to deliver Raboral V-
RG® does not contain biomarker, which would have aided in this evaluation.  Considerable 
variation in RVNA has been observed 2007 to 2010 in the general vicinity of the Virginia 
reference area, with levels ranging from18.4 (n=114; 2010) to 39.0 percent (n=210; 2007) (Table 
10). As an index, 11 percent (5/45) of ORV events examined during a 3-year period (2006 to 
2008) at 75 baits/km2  from 12 eastern states  exceeded the sero-positive rate observed in this 
field trial.  The mean sero-positivity was 32.3±12.8 (SD) percent for these 45 ORV events.  
RVNA for all of these ORV events was in relation to areas that had been baited at least twice;  
most had been baited for several successive years. However, given this rare high level of 57.1 
percent, we plan to evaluate the same ORV area in Virginia in 2012, with a similar sampling cell 
format as used in West Virginia. In addition, formal sampling cells are being planned for pre- 
and post-ORV within the Raboral V-RG® and the ONRAB® zone in West Virginia in 2012. This 
design improvement will facilitate determining if population immunity will increase significantly 
in response to a second successive year of ONRAB® baiting at 75 baits/km2 and allow for a more 
formal comparison with Raboral V-RG®. 
An inadequate sample of skunks was captured to establish a population baseline for RVNA and 
evaluate the response to ONRAB®.  Only one of 20 skunks had detectable RVNA in the Pre-
ORV sample; one of 27 had RVNA post-ORV with ONRAB® (Table 5). All other species in 
Table 5 are reflective of incidental captures of rabies reservoir species in North America 
(Blanton et al., 2011). 
There was no evidence of HAd5 antibodies in 416 animals sampled during the pre-ORV period 
(Appendix E). Seven of 296 (2.4%) samples evaluated post-ORV demonstrated HAd5 VNA; 6 
raccoons and 1 skunk (Appendix F). Low seroconversion may be expected for a human adapted 
virus. Monitoring for anamnestic responses will be incorporated into the evaluation of baiting 
with ONRAB® in after a second baiting as projected for September 2012. 
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Histopathology 
Field study  
Diverse fauna were sampled for histopathological analysis in the pre and post-ONRAB® periods. 
Small rodents such as Peromycus sp. and Microtus sp. constituted the largest group sampled that 
included other rodents, lagomorphs, cervids and birds (Table 11). The results are not available at 
this time, but will be provided as an addendum to this report after they are received from MD 
Anderson Cancer Center (Houston, Texas, USA). Our expectation is that these results will be 
available by the end of April. 
Captive study  
The species selected for captive studies represent common fauna to southeastern West Virginia 
and will serve to complement the spectrum of species that have already been evaluated for 
histopathologic effects relating to ONRAB® exposure in Canada (Knowles et al., 2009). Similar 
histopathologic results in vaccinates and control animals were observed for the four species in 
which the analysis is completed, suggesting no untoward effects from ONRAB® consumption at 
a 10x dose above exposure to single bait. The woodrat analysis is nearing completion. The 
results from this captive study in tandem with previous results from Canada (Fehlner-Gardiner et 
al., 2012) serve as the reference for histopathology from wildlife in southeastern West Virginia.  
The summary report from the captive histopathology study submitted by WS, NWRC is in 
Appendix G. 
ONRAB® Detection from Oral Swab Sampling Day 1 – 6 Post-ORV  
Swab samples were collected from 125 target and nontarget individuals live-trapped from day 1-
6 post ORV baiting to determine ONRAB® presence in the oral cavity.  Individual raccoons 
captured on days 2, 3 and 4 and an opossum on day 4 had qPCR values <35, which are 
considered strong positives (Knowles et al. 2009) (figure 8). An additional nine raccoons and 
four opossums  with >35 qPCR values <40 were captured on days 1-4.  No ONRAB® was 
detected on days 5-6. Two of 15 raccoons and two of 12 opossums had >35 qPCR values <40 on 
day 1.  While these are not considered strong positives, they represent the only animals sampled 
that could have had vaccine contact during the first night after ONRAB® distribution.  It is not 
possible to determine the specific day in which vaccine contact may have occurred for remainder 
of the animals deemed positive from day 2-4. 
ONRAB® Bait Contacts 
No human or domestic animal bait or vaccine contacts were reported to the WVDOH or WS 
associated with the ONRAB® field trial in 2011, despite notification of the field trial and media 
events that included bait descriptions and the integration of enhanced to document potential bait 
exposures and reduce potential safety issues.   
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Enhanced surveillance and tracking of bait and vaccine contacts are an integral component of 
ORV projects conducted by WS in the U.S. (Roess et al. 2012). About 120 million Raboral V-
RG®  baits have been distributed since the WS ORV program inception in 1995, yet only 1,464 
people reported contacting or potentially contacting a bait (i.e., picking up bait, finding a bait in 
yard, or removing bait or sachet from pet’s mouth, feces, or vomit - any type of contact with a 
bait is also defined throughout the document as an “exposure”).  This equates to one human 
exposure per 68,521 baits distributed, or 0.0015% contact cases (U.S. Department of Agriculture, 
2011b).  In addition, exposure cases were generally insignificant, as most involved finding an 
intact bait.  Very few cases involved touching a broken bait, sachet, or liquid vaccine.  
Furthermore, of the 0.0015% of contact cases reported since 1995, only two known adverse 
reactions have been reported (USDA 2010a; CDC 2009).   
From 1995 - 2008, U.S. Department of Agriculture (2011b) documented only 1,327 instances 
where a pet or other domestic animal had contact with a bait.  This equates to 1 domestic 
exposure per 75,596 baits disbursed or 0.001 % contact cases.  In addition, U.S. Department of 
Agriculture (2011b) documented that 261 incidents were reported in which pets came into 
contact with a bait in 2008. However, there were no reports of pets or other domestic animals 
experiencing any type of adverse reaction, other than 8 dogs who experienced vomiting or 
diarrhea after ingesting a number of baits.  The dogs involved in these adverse reactions have 
reportedly not experienced any substantive or long term adverse effects.  Domestic animals that 
bite into and ingest a bait of either Raboral V-RG® or ONRAB® are most likely to be immunized 
against rabies virus or receive a boost from a previous vaccination.   
 As in the U.S., ONRAB® baits distributed in Canada are marked with a toll-free number that the 
public can call if they see or have contact with bait or vaccine. Between 2006 and 2011 over 3.9 
million ONRAB® baits were distributed in Ontario. There were a total of 64 calls received in 
which a person reported finding or contacting a bait during this period.  This equates to 
approximately 1 call for every 65,140 baits distributed or 15 calls for every 1 million baits 
distributed, essentially the same as the call rate for Raboral V-RG®.  The total number of calls 
received involving possible contact (i.e. vaccine contact not officially confirmed) with vaccine as 
a result of handling a punctured bait or removing a bait from a dog’s mouth or dog chewing a 
bait was 15.  The rate of possible contact with vaccine equates to 1 contact for every 260,560 
baits distributed.  There were no reports of adverse events associated with humans from any of 
the reported contacts (Ontario Ministry of Natural Resources 2007, 2008, 2009, 2010, 2011).  
The province of Quebec has also been distributing ONRAB® vaccine baits since 2007. Between 
2007 and 2009, despite the distribution of almost 2 million baits, there were only 16 reports of 
human exposures (Mainguy and Canac-Marquis unpublished).  In 2010, just over 1 million 
ONRAB® baits were distributed with no human bait contacts reported (Ontario Ministry of 
Natural Resources, 2011) 
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The relatively low numbers of bait and vaccine contacts associated with ONRAB® in Canada and  
no reported bait or vaccine exposures documented during this field trial in the U.S. could be 
related to several factors. The ONRAB® ULTRALITE bait differs from Raboral V-RG® baits 
(coated sachets and fishmeal polymer baits) in color and attractants.  The ONRAB® bait matrix is 
a khaki green color, which may aid in camouflaging in most habitats.   Also, the ONRAB® baits 
contain a sweet scent and flavor rather than scent associated with fishmeal for Raboral V-RG®, 
which may decrease the likelihood of baits being found by cats and dogs.  Maintaining a system 
for enhanced surveillance for human and domestic animal bait contact will be important as field 
trials expand to other areas that include more urban and suburban habitats with increased human 
and pet populations that often require higher baits densities to meet management objectives.  
RECOMMENDATIONS 
The following recommendations are the result of the encouraging outcome of this initial 
ONRAB® field trial. 
1) The West Virginia trial should be replicated and include at least two similar sized, 
buffered sampling cells in the adjacent Raboral V-RG® ORV zone for comparative 
purposes.  Pre and Post-ORV raccoon and skunk samples should be collected at sufficient 
sample size for RVNA serological analysis to address the question: does a successive 
second year of ONRAB® vaccination significantly increase raccoon population immunity 
above year one?  These data will be required as a basis for year three ORV to determine 
if the population immune response becomes asymptotic at year two similar to the pattern 
generally observed for Raboral V-RG®, but at a significantly higher level.  Leveling off 
of the population immune response should in turn be analyzed in the context of raccoon 
age structure, which is likely a correlate as a reflection of population dynamics. 
2) Field trails should be expanded in 2012 to areas with an elevated risk of raccoon rabies 
spreading to naïve areas.  The Ohio Contingency Action zone (east of Cleveland, Ohio) , 
which is interspersed with urban and suburban development, represents the highest 
priority site and is ideally suited for an evaluation of safety with respect to bait contacts 
and immunogenicity associated with hand baiting at 150 baits/km2.  This proposed 
expansion would introduce new complexities associated with unique bait distribution 
patterns that should be evaluated for broader use of ONRAB®.  As a results of trap-
vaccinate-release efforts in the Ohio Contingency Action zone, a history of raccoon 
populations and RVNA exists.  The challenge will be to focus sampling effort on the 
naïve juvenile class as well as the overall population immunity for evaluating the post-
ORV with ONRAB® treatment.  In addition, measuring bait contacts under higher bait 
and human densities represents a key area of interest. 
3) In 2006, raccoon rabies was first confirmed in Quebec, with Vermont as the likely source 
of the emergence of this rabies virus variant. Since 2006, Quebec has made extensive 
commitments to raccoon rabies control and surveillance (Rees et al., 2011). No cases of 
raccoon rabies have been detected in the Province since May 2009, with the use of 
ONRAB® central to their strategy for elimination. Quebec has expressed an interest in 
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creating a greater distance buffer to enhance protection against the emergence of raccoon 
rabies in Montreal.  Therefore, a field trial in northern Vermont and New Hampshire and 
Northeastern New York should be elevated in priority to prepare for collaboration with 
Quebec and the likelihood of a commitment of Quebec resources to this effort in 2013. In 
the U.S., this area is largely rural, not unlike West Virginia, but the field trial would 
occur in an area that has been subject to ORV and trap-vaccinate-release (TVR). This 
field trail should be structured to allow for a comparison of naive areas in Vermont to 
similar areas in West Virginia, as well as first ONRAB® baiting in previously vaccinated 
(Vermont) and (unvaccinated) areas (West Virginia). 
4) The Niagara Frontier, connecting New York and Ontario, represents another high risk 
corridor for raccoon rabies movement and therefore is a priority for a future field trial in 
2012, or more likely 2013, depending on available resources and other factors.  TVR had 
been used for several years between the Welland Canal and the Niagara River in Ontario 
to provide an immune barrier against spread and establishment of raccoon rabies from 
New York.  In New York, ORV with Raboral V-RG® has been in place on the Niagara 
Frontier since 1996 (U.S. Department of Agriculture, 2007), with rabies perpetuating in 
raccoons and skunks in Erie and Niagara Counties, New York, which border Canada.  
The Niagara Frontier includes the City of Buffalo and Niagara Falls, and as such has 
some similarities with the proposed field trial area east of Cleveland, Ohio. 
5) In 2013, the St. Lawrence River Valley, New York and northeastern Tennessee represent 
high risk areas that should be considered as field trial sites, if additional field data are 
required to support the licensing of ONRAB®.   
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TABLES 
Table 1.  List of county, state, federal and international entities from governments and non-government 
organizations that collaborated and participated in the West Virginia ONRAB® field trial, 2011. 
Agency/Organization Name 
United States Department of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services, National 
Wildlife Research Center (USDA, APHIS, WS, NWRC) 
USDA, APHIS, Center for Veterinary Biologics (CVB) 
USDA, APHIS, Legislative and Public Affairs (LPA) 
USDA, APHIS, Policy and Program Development (PPD) 
Centers for Disease Control and Prevention (CDC)  
United States Forest Service (USFS) 
West Virginia Department of Agriculture 
West Virginia Department of Health and Human Resources 
West Virginia Division of Natural Resources 
Greenbrier, Monroe and Summers County Commissioners 
Animal Health Diagnostic Center, Cornell University College of Veterinary Medicine 
Ontario Ministry of Natural Resources 
Quebec Ministère des Ressources naturelles et de la Faune 
Canadian Food Inspection Agency 
Trent University 
Artemis Technologies, Inc. 
Dynamic Aviation Group, Inc. 
 
Table 2.  Candidate oral rabies vaccines considered for field testing in the U.S. over the past five years. 
Vaccine ONRAB® SAG2 CAV2 SPN SASGAS 
Recombinant? yes no, modified-live yes yes, reverse genetics 
Licensed in U.S.? no no no no 
Licensed outside U.S.? pending yes no no 
Interest in U.S.? yes yes yes yes 
Proprietor1 Artemis Virbac MTTI IDT 
1 Artemis Technologies, Inc. (Ontario, Canada); Virbac (Carros, France); Molecular Targeting Technologies, Inc. (Pennsylvania, USA); IDT 
Biologika (Dessau, Germany). 
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Table 3.  Pre- (baseline) and post-ONRAB® oral rabies vaccine sampling emphasis. 
Activity Pre-ONRAB® Post-ONRAB® 
Enhanced rabies surveillance yes yes 
Rabies virus serology yes yes 
Human adenovirus  serology yes yes 
Biomarker yes yes 
Histopathology (target and non-target species) yes yes 
Oral cavity swab samples no yes 
Monitoring for abnormalities among animals yes yes 
ONRAB® bait contacts n/a yes 
 
Table 4.  Percent of sero-converted raccoons and corresponding sample size for pre- and post-ONRAB® baiting. 
  
Adult Male Adult Female Juvenile Male Juvenile Female 
Interval Cell % n % n % n % n 
Pre-bait 1 3.9 32 1.9 31 0.0 21 0.0 17 
 
2 4.1 41 4.1 27 2.0 18 0.0 10 
 
3 4.4 49 3.6 33 0.8 12 0.8 15 
 
4 5.9 24 1.1 25 0.0 12 3.6 20 
Post-bait 1 21.6 27 8.4 27 7.2 16 4.8 13 
 
2 14.6 14 17.1 8 9.7 11 7.3 8 
 
3 37.3 28 25.4 25 5.1 4 1.7 2 
 
4 25.0 39 16.2 30 1.2 7 0.0 4 
 
Table 5.  Percent of sero-converted animals sampled for pre- and post-ONRAB® field trial in West Virginia, 2011. 
 
Pre-ONRAB® Post-ONRAB® 
Species % n % n 
Raccoons 9.6 395 49.4 263 
Striped skunks 5.0 20 3.7 27 
Gray foxes 0.0 1 100 2 
Red foxes 
 
0 66.7 3 
Coyotes 
 
0 100 1 
Total 9.4 416 45.9 296 
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Table 6.  Percent of sero-converted raccoons where Raboral V-RG® oral rabies vaccine was distributed for the first 
time following baseline sample collection in an ORV naive area and indexes to raccoon population density in 
eastern states (2001-2009).1 
State Year 
Bait Density (per 
km2) % n Region2 
Mean 
Raccoon 
Density 
n 
Studies 
     
 
Alabama 2002 naive 2.9 68 
Georgia-Alabama-Tennessee 
(GAT) 
   
 
2003 75 32.8 67 
Georgia-Alabama-Tennessee 
(GAT) 6.5 2   
  2002 naive 11.3 ## Selma       
  2004 75 13.1 99 Selma 8.9 2   
 
2005 naive 1.2 84 Birmingham 
   
 
2005 75 2.7 ## Birmingham n/a 0  
Florida 2003 naive 9.1 99 Mainland (not Pinellas County)       
  2003 75 9.2 65 Mainland (not Pinellas County) 17 5 
     
 
Georgia 2003 naive 0 19 
Georgia-Alabama-Tennessee 
(GAT) 
   
 
2004 75 30.2 ## 
Georgia-Alabama-Tennessee 
(GAT) n/a 0  
Maine 2002 naive 14.3 21 Hodgdon       
  2003 naive 0 11 Hodgdon       
  2003 70 19.5 82 Hodgdon 3.6 2   
 
2007 naive 1.4 74 Caribou 
   
 
2009 75 26.4 ## Caribou 12.1 2   
North 
Carolina 2005 naive 3.3 30 Appalachian Ridge       
  2005 75 7.5 ## Appalachian Ridge n/a 0  
Pennsylvania 2002 naive 9.9 ## Appalachian Ridge 
   
 
2002 75 12.8 39 Appalachian Ridge n/a 0  
Tennessee 2002 naive 3.3 30 Appalachian Ridge       
  2002 75 10.8 74 Appalachian Ridge 9 1  
Virginia 2001 naive 9.1 33 Appalachian Ridge 
   
 
2002 naive 3.4 29 Appalachian Ridge 
     2002 75 22.1 68 Appalachian Ridge 4.7 2   
Total   naive mean=4.9±4.8 n=13         
Total   70/75 mean=17.0±9.9 n=11         
1 Information subject to minor change based on revised data entry to Wildlife Services' Management Information System; accessed March 2012. 
2 Regions represent distinct ORV zones within a given state where sampling was conducted independent of other regions. 
3 Means and standard deviations of naive vs. baited areas were generated from 13 and 11 events, respectively (n=13, n=11). 
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Table 7.  Raccoon density indexes within or near ONRAB® field trial area in West Virginia, 2006-2010. 
Year Study Name County Density (raccoons/km2) Area Habitat Class 
2006 WVGREENB06 Greenbrier 8.2 Rural (mixed forest) 
2007 WVGREENB07 Greenbrier 12.2 Rural (mixed forest) 
2010 WV00310 Greenbrier 12.0 Agriculture (pasture/hay) 
2010 WV00410 Greenbrier 10.7 Rural (mixed forest) 
2010 WV00510 Monroe 6.6 Rural (mixed forest) 
2010 WV00610 Monroe 7.0 Rural (mixed forest) 
 
Table 8.  Seroconversion and biomarker results for 341 raccoons sampled prior to ONRAB® ORV distribution in 
West Virginia, 2011. 
Pre-ORV  
Biomarker Negative Biomarker Positive 
 
male female male female 
Sero-negative adult 117 87 5 6 
 
juvenile 38 43 11 3 
Sero-positive adult 15 9 1 1 
 
juvenile 3 1 1 0 
 
Table 9.  Seroconversion and biomarker results for 250 raccoons sampled after ONRAB® ORV distribution in West 
Virginia, 2011. 
Post-ORV  
Biomarker Negative Biomarker Positive 
 
male female male female 
Sero-negative adult 33 41 7 5 
 
juvenile 19 13 4 5 
Sero-positive adult 41 28 19 13 
 
juvenile 2 4 12 4 
 
Table 10.  Percent of sero-converted raccoons sampled post-ORV (Raboral V-RG® in West Virginia and Virginia, 
2007-2011. 
 
West Virginia Virginia 
Year % n % n 
2007 46.4 84 39.0 210 
2008 18.5 135 32.0 147 
2009 24.0 179 18.8 319 
2010 20.5 239 18.4 114 
2011 no sampling conducted 57.1 177 
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Table 11.  Number of histopathology samples collected pre- and post-ORV during the ONRAB® field trial in West 
Virginia, 2011. 
Species Pre-ONRAB® Post-ONRAB® 
Bear (Ursus americanus) 4 1 
Coyote (Canis latrans) 3 3 
Crow (Corvus brachyrhynchos) 9 9 
Deer (Odocoileus virginianus) 4 2 
Fox (Urocyon cinereoargenteus and Vulpes vulpes) 3 3 
Opossum (Didelphis virginiana) 9 10 
Rabbit (Sylvilagus floridanus) 8 9 
Raccoon (Procyon lotor) 9 10 
Rodents, small (Peromyscus and Microtus spp.) 201 221 
Skunk (Mephitis mephitis) 7 4 
Squirrel (Sciurus carolinensis and Sciurus niger) 13 10 
Vulture (Cathartes aura) 10 8 
Woodchuck (Marmotamonax) 10 10 
Total 290 300 
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FIGURES 
 
Figure 1.  Raboral V-RG®  oral rabies vaccine distribution targeting raccoons, gray foxes and coyotes in the United 
States, 1992-2011. 
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Figure 2.  Oral rabies vaccine distribution zones targeting raccoons, gray foxes and coyotes in the United States, 
2011.  Inset includes ONRAB® ORV zone relative to Raboral V-RG® zone and ONRAB® sampling cell details. 
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Figure 3.  ONRAB® baits utilized in oral rabies vaccine field trial in West Virginia, 2011.  (Photo: 
http://www.mnr.gov.on.ca/en/Business/Rabies/2ColumnSubPage/STEL02_166285.html accessed March 2012.) 
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Figure 4.  Preselected random trapping points and subsequent raccoons and skunks captured during pre- and post-
ONRAB® trapping periods in West Virginia, 2011. 
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Figure 5.  Suggested standard operating procedure (SOP) for documenting and managing human contacts with 
ONRAB® baits during field trial in West Virginia, 2011. 
  
LOW RISK. 
FOLLOWUP AS 
NEEDED.
YES
WAS ONRAB 
BAIT INTACT?
LOW RISK. 
FOLLOWUP AS NEEDED.
WAS THERE  DIRECT 
EXPOSURE TO SACHET 
CONTENTS (vaccine)? 
If >1 contact, complete 
SOP for each contact.
WAS THERE INDIRECT 
EXPOSURE TO SACHET 
CONTENTS (vaccine) THROUGH 
CONTACT WITH EXPOSED 
PERSON OR ANIMAL?
1. CONTACT PERSONAL PHYSICIAN (with patient permission)
2. CONTACT APPROPRIATE STATE AND COUNTY PERSONNEL
3. CONTACT CDC1 FOR CONSULTATION
IMMUNOCOMPROMISED?
PREGNANT? 
MUCOSAL OR EYE EXPOSURE? 
VACCINE HAD CONTACT WITH 
OPEN OR BREACHED SKIN?
NO
NO
YES
YES
YES
1.  CONTACT PATIENT’S PERSONAL PHYSICIAN (with patient permission)
2.  CONTACT APPROPRIATE STATE AND COUNTY PERSONNEL
3.  CONTACT CDC1 FOR CONSULTATION INCLUDING DIAGNOSIS AND TREATMENT
4.  STATE HD, CDC, AND TREATING PHYSICIAN CONFERENCE CALL TO DISCUSS CASE 
MANAGEMENT
WEEKLY FOLLOWUP CALLS FOR 3 
WEEKS (at least once 10-14 days 
post exposure). 
PATIENT IS ENCOURAGED TO CALL 
IF THERE IS ANY ILLNESS.
ANY ILLNESS?
END FOLLOWUP 
AFTER 3RD WEEK.
NO
YES
NO
NO
SUGGESTED SOP FOR ONRAB ORAL RABIES VACCINATION BAIT CONTACTS (HUMAN)
*Please note this is a suggested SOP.  State and county HDs are not required to follow this SOP and may alter the components to accommodate their program.*
LOG CALL.  FILL OUT FORM FOR ALL CALLS INVOLVING CONTACTS – INDIRECT AND DIRECT CONTACT, INTACT AND OPEN BAITS.
1CDC Emergency Operations Center: 770-488-7100
*This document was originally created for V-RG ORV by Andrea McCollum and Brett Petersen (ige3@cdc.gov), 
2010 and modified by Richard Chipman (richard.b.chipman@aphis.usda.gov) for ONRAB in 2011.  
The content is based on information and SOPs from USDA, TX, and OH.   
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Figure 6.  Raccoon rabies variant case history in West Virginia 2007-2011 within an 83 km radius of the center of 
the 2011 ONRAB® ORV zone. 
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Figure 7.  Raccoons sampled for rabies virus neutralizing antibodies (RVNA) post-ORV Raboral V-RG®  
distribution and cases of raccoon rabies virus variant within an 83 km radius of the center of the sampled raccoons, 
Virginia, 2011. 
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Figure 8.  Total unique captures for oral swab sampling and PCR positives by species, day 1-6 post-ORV with  
ONARB® distribution September 16,  2011 (others included gray squirrel and cottontail rabbit). 
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APPENDICES  
Appendix A: Final Outline for Proposed ONRAB® Oral Rabies Vaccine Field Trial in West 
Virginia 
1) Site location (Figure 1) 
 State: Southeastern West Virginia 
 Counties: portions of Greenbrier, Monroe, Summers  
 Towns:  Alderson, Fairlea, Falling Springs, Lewisburg, Ronceverte 
 Field trial plot coordinates: 38.044, -80.421; 37.920, -80.241; 37.566, -80.932; 37.445,  
-80.753. 
2) Rationale for field trial site selection 
 Near the strategic center of the Appalachian Ridge ORV zone created with Raboral V-
RG®  
 Raccoons and skunks present 
 Raccoon rabies perpetuates east of existing ORV zone 
 Proposed zone in a single state 
 Local support within state and county 
 Low human population 
 WS infrastructure in place 
 Site allowed for a broader seasonal window for baiting than potential sites farther north 
3) Field trial plot size 
 Total area:  1,478.11 km2  [1,450.28 km2 (fixed wing baiting) and 27.83 km2 (ground 
baiting)]  
 4 distance buffered cells: 11.2 x 11.2 km post-ORV sampling cells:  126.84 km2 
4) Baiting characteristics 
 Total baits:  79,594  (78,016 fixed wing and 1,578 ground)  
 Bait density:  75 baits/km2 
 Flight line spacing:  750 meters  
 Off-time:  28% for fixed wing and 24% for ground using NLCD to determine “baitable” 
habitat  
 Projected baiting dates:  September 15-16, 2011 
 Baiting duration: 2 days, 1 plane and ground crews for hand-baiting 
5) Bait-vaccine characteristics 
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 Each bait contains 1.8 ± 0.1ml of ONRAB® vaccine (titer of not < 109.5 cell culture 
infectious dose 50% [CCID50]/ml) 
 Bait matrix is comprised of partially hydrogenated vegetable shortening (34%), 
Microbond® wax (30%), stearine (12.5%), Icing sugar (20%), vegetable oil (1%), 
artificial marshmallow flavor (1%), artificial sweet flavor (1%), and a fat-soluble food 
dye (0.5%) 
 Bait matrix contains 100 mg of tetracycline hydrochloride as a biomarker 
 Each vaccine-bait weighs approximately 4g 
 The body of the blister pack is an elongated oval with dimensions of 1.81 x 0.55 x 0.39in 
(30x14x10mm) 
 Each bait contains a conspicuous advisory label with a toll free number in the event of a 
bait contact and potential vaccine exposure  
6) Pre-ORV sampling (baselines) 
 Enhanced rabies surveillance has been in place for > than 1 year 
 Early baseline raccoon and skunk samples collected in 2010 from 5 density index sites 
 In late summer 2011, 150 raccoon-sized cage traps will be tended for 10 consecutive days 
within each of the 4 buffered sampling cells 
 Traps will be deployed at random roadside trapping locations 
 Focus is to characterize target and non-target  community 
 Expect capture rate at  >100 raccoon/cell based on recent previous trapping efforts in area 
 Maximize skunk captures by additional targeted trapping if needed 
 Collect pertinent biological, physical and spatial-temporal data from live captured 
raccoons and skunks and sera for rabies and human adenovirus serological analysis 
 Euthanize target species with unusual lesions or behaviors for pathological analysis 
 Late spring/summer 2011 collect nontarget tissue and sera from 5-day trapping studies 
for serological and histopathological analysis  
 Implement continuous opportunistic sampling for target and nontarget species (e.g., 
roadkills) for histopathological analysis  
7) Post-ORV sampling (treatment effects)  
 Continue enhanced rabies surveillance 
 Continue opportunistic sampling for target and nontarget species (e.g., roadkills, hunter 
harvest) for histopathological analysis for up to 1 year post ORV 
 Upon completion of ORV  collect buccal and anal swab samples and other pertinent 
biological, physical and spatial-temporal data from target species for a 10-day period for 
virus detection/isolation 
 Beginning 2 weeks post-ORV collect nontarget organ tissue and sera from 5-day trapping 
studies for serological and histopathological analysis 
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 5 weeks post ORV sample ≥100 raccoons and as many skunks as practical within each of 
the 4 buffered cells using the pre-ORV target species trapping protocol 
 Collect pertinent biological, physical and spatial-temporal data from raccoons and skunks 
as well as sera for rabies and human adenovirus analysis 
 Monitor for abnormalities in captures/animals reported and collect samples as appropriate 
8) Sample Analysis  
 Rabies virus serological titers to be determine by CDC 
 Human adenovirus titers potentially determined at Cornell 
 Histopathological analysis sources to be finalized 
9) Captive pen safety studies at NWRC (separate protocol for review) 
 Species of concern: opossum, fox squirrel, wild turkey, cottontail and wood rats.  
10) Report Findings 
 Expect results from analysis of field data by March 1, 2012  
 Draft report by May 1, 2012 
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Appendix B: Post-ORV Sampling to Detect Human Adenovirus Serotype-5 as a Part of the 
September 2011 ONRAB® Field Trial, Southeastern West Virginia 
Trapping design and animal handling 
Samples will be collected day 1 through day 6 to obtain buccal and anal swab samples from live-
trapped target and non-target species for PCR and virus isolation.  Fifty live traps should be set 
the day of ONRAB® (Artemis Technologies, Guelph, Ontario, Canada) distribution within the 
three intercellular spaces between the four sampling cells (Figure 1).  This spatial trapping 
design should minimize trap “happiness” or “shyness” within the raccoon and skunk populations 
in the four sampling cells that will be trapped five weeks post-ORV.  Traps should not be set in 
buffer areas to eliminate edge effects. 
All captured animals will be handled according to WS’ SOP used by the NRMP.   
Swab sampling, processing and shipping 
Swab samples will be collected from all target and non-target species captured during the first 6 
days post-ORV using this design.  
Once each live-trapped animal is anesthetized or in some cases euthanized (if warranted based on 
signs or other factors), duplicate buccal and duplicate anal swab samples should be obtained 
immediately using BD* Universal Viral Transport Kits (see vendor information under Supplies 
at the end of this Appendix).   
Thoroughly swab the inside of the mouth ensuring the each swab makes contact within the 
mouth (e.g., tongue, roof, etc.). Place each swab into a properly labeled 1 mL viral media vial, 
snap off the swab, properly seal each vial and immediately place on dry ice or in a freezer 
(following vendor instructions). For anal swab samples, insert the swab into the anus the length 
of the swab tip and gently complete one rotation and place each swab into the 1 mL viral media 
as detail for buccal swabs.  Place all swabs immediately on dry ice.  Cooling quickly is a critical 
step. 
Each day (or every other day) samples should be sent by overnight mailed on dry ice to the 
following address: 
Dr. Edward Dubovi 
Animal Health Diagnostic Lab 
College of Veterinary Medicine 
Upper Tower Road 
Ithaca, NY 14853 
607-253-3923 
 
ONRAB® (Human Adenovirus Serotype-5) Oral Rabies Vaccine Field Trial Report, West Virginia - 2011 
B-2 
 
An email with courtesy copy to Kathleen Nelson (knelson@aphis.usda.gov) should be sent to Dr. 
Edward Dubovi(ejd5@cornell.edu) informing him that samples have been sent.  Include an excel 
spreadsheet with data and the UPS tracking number.  Do not ship samples on Fridays unless 
otherwise instructed to do so. 
Recording data 
If data collection is in MIS: Collect standard information for each capture, plus record time of 
day each sample was collected. Time of sample collection/capture can be obtained by using the 
time the animal was anesthetized from the PDA database file (dbf).  The dbf file should be 
retained to recall time of day for each capture, as this information is not uploaded to the MIS. 
If data collection is outside of MIS: Collect data for the following fields: date, time of day, 
latitude, longitude, species, sex, relative age, swab sample (yes or no), comments. 
Supplies 
BD* Universal Viral Transport Kits may be purchased at Fischer Scientific, catalog number: 22-
031-15.  
http://www.fishersci.com/ecomm/servlet/fsproductdetail?storeId=10652&productId=13751252&
catalogId=29104&matchedCatNo=2203115&endecaSearchQuery=%23store%3DScientific%23
N%3D0%23rpp%3D15&fromSearch=1&searchKey=031||22||15&highlightProductsItemsFlag=
Y 
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Appendix C: Materials and Methods Used in qPCR Screening of Human Adenovirus 
Serotype-5  Rabies Virus Glycoprotein Recombinant Vaccine (ONRAB®) 
Animal Health Diagnostic Center, Cornell University 
January 19, 2012 
 
Primers and probe for ONRAB® qPCR assay 
The primers and probe sequences for the ONRAB® qPCR assay were from Knowles et al. 
(2009a, 2009b). Primers were synthesized by Invitrogen and were purified by desalting.  The 
probe was sourced from Sigma Life Science and was HPLC purified. 
AdRG-For CAACTGTCCTAACCTTGGATTACATCA   HAd5 (upstream of rabies G) 
AdRG-Rev GAATTTCCCAAAACACAATGGAA    rabies G gene 
AdRG-probe FAM™-AGGCTCTCCTGTTTGTACCCCTTCTGGTT-BHQ®1 rabies G gene 
 
Positive amplification control and assay verification 
A positive amplification control (PAC) amplicon was generated using primers that flank the 
assay target region. 
Ad5E3-F   GCGGACGGCTACGACTGAATGTTA 
RVG-R      TTGTTTGGGCAGCTGAGGTGATGT 
 
Vaccine was drawn directly from an ONRAB® bait and nucleic acid was extracted from a 200 µl 
volume (Qiagen #69504). The PAC fragment was amplified from the purified DNA using a 
commercially available PCR mix (Invitrogen, #11306-016) and a conventional thermocycler 
(Stratagene Robocycler).   
Cycling conditions were 94oC for 2 min, followed by 35 cycles of 94oC for 30 sec, an annealing 
temperature for 30 sec, and 72oC for 1 min. The annealing temperature gradient included 
reactions at 55oC, 57oC, 59oC and 61oC. Gel electrophoresis confirmed single bands in reactions 
at all annealing temperatures.  The reactions were pooled and purified (Qiagen #28106). The 
purified PAC was quantified spectrophotometrically (Nanodrop 1000) and the copy number was 
calculated.   
An Applied Biosystems (ABI) Path-ID kit (#4388644) was used for PCR amplification. Forward 
and reverse primers were used at a concentration of 400 nM and the probe was used at a 
concentration of 120 nM.    Four µl of the PAC dilution series, ranging from 1 × 107 copies /4 µl 
to 1 × 10-1/4 µl, was used per reaction, in a total volume of 25 µl. Three initial test runs were 
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conducted on a SmartCycler 2 thermocycler (Table 1 and Figure 1).  Cycling conditions were 
95oC for 10 min, followed by 40 cycles of 95oC for 15 sec, 60oC for 1 min. A subsequent run of 
the PAC dilution series on an ABI 7500 thermocycler gave equivalent Ct values at each dilution 
and an overall amplification efficiency of 101.8% (not shown).  The PAC dilution amplification 
series showed the assay to be consistently sensitive to a level of detection approximating 10 
copies of viral DNA. 
Table 1.  Example summary of a run showing the Ct values of the PAC dilution series. 
 
  
Run Summary        (Smart Cycler 2.0d)
Run NameOnRab Test 1 11-7-11
Started At 11/7/2011 16:42
Number o  10
Results Table
Site ID Protocol Sample ID Sample TNotes Status FAM Std/Res FAM Ct
A1 PATH ID qPCR ntc UNKN OK ND 0
A2 PATH ID qPCR 10^-1 STD OK 0.1 0
A3 PATH ID qPCR 10^0 STD OK 1 0
A4 PATH ID qPCR 10^1 STD OK 10 35.98
A5 PATH ID qPCR 10^2 STD OK 100 31.33
A6 PATH ID qPCR 10^3 STD OK 1000 27.86
A7 PATH ID qPCR 10^4 STD OK 10000 24.47
A8 PATH ID qPCR 10^5 STD OK 100000 21.15
A9 PATH ID qPCR 10^6 STD OK 1000000 17.39
A10 PATH ID qPCR 10^7 STD OK 10000000 14.44
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Figure 1.Upper panel shows the amplification plot of PAC dilution series.  The lower panel shows the standard 
curve generated from the data in Table 1 (Efficiency = 91.5%). 
 
Purification and qPCR of samples 
Swabs were received in universal viral transport tubes (Becton Dickinson, #220222) containing 3 
ml of transport medium.  Nucleic acid (NA) was purified from 175 µl of the medium using a 
MagMax total Nucleic Acid Isolation Kit (ABI #1840).  Purified NA was eluted in a final 
volume of 50 µl. 
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The ABI Path-ID mastermix (#4388644) was used for PCR amplification. Forward and reverse 
primers were used at a concentration of 400 nM and the probe was used at a concentration of 120 
nM.  Four µl of purified NA was used per reaction in a total volume of 25 µl.  The qPCR 
reactions were run in 96-well plates on an ABI 7500 thermocycler. Cycling conditions were 
95oC for 10 min, followed by 40 cycles of 95oC for 15 sec, 60oC for 1 min. 
In addition to the test samples, each set of reactions included at least two negative control wells 
(NTC), a positive extraction control (PEC) well with ONRAB® vaccine diluted at 1 × 10-5 in 
transport medium, a negative extraction control (NEC) consisting of transport medium only, and 
a PAC well with a calculated copy number of 100. 
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Appendix D: Safety of ONRAB® in Select Captive Non-target Species 
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Appendix E: Human Adenovirus Serotype-5 Titers Pre-ONRAB® 
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Appendix F: Human Adenovirus Serotype-5 Titers Post-ONRAB® 
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Appendix G: Histopathology Results from Captive Studies at Wildlife Services, NWRC 
Dr. Kurt VerCauteren, Rabies Research Project Leader 
ONRAB®, like Raboral V-RG®, is a recombinant vaccine. However, the viral vector in 
ONRAB® is human adenovirus type 5 (Had5).  Had5 is a relatively safe and well-studied virus, 
which is used in many vaccine formulations. Wild-type Had5 often causes mild respiratory or 
gastrointestinal manifestations in humans, although immunocompromised individuals may 
develop a more serious disease (Textbook of Pediatric infectious diseases, Vol 2: Ralph Feigin). 
Extensive studies on the efficacy and safety of the ONRAB® vaccine in animals have been 
completed in Canada (Yarosh et al. 1996, Lutz-Wallace et al. 1995,  Randrianarison-Jewthoukoff 
and Perricaudet 1995, Rosette et al. 2009, Knowles et al. 2009), and the encouraging findings of 
these studies initiated ONRAB’s  distribution via aerial bait drop in 2006 targeting raccoons and 
skunks.  Rabies VNA seroconversion rates in areas baited with ONRAB® averaged 80% in the 
first two years (Rosatte et al. 2009), well above the seroconversion rates when the vaccine 
Raboral V-RG®  is used (Slate et al. 2009, Brown et al. 2010). 
For the non-target safety studies in the literature, researchers administered an ONRAB® dose 10 
times the dose needed to vaccinate target species. Animals were monitored daily and all tolerated 
exposure to the vaccine. Analyses of tissues resulted in viral RNA detected in some lung and 
kidney samples. Following histopathological analysis, the most marked findings were in the 
lungs with pulmonary congestion and some possible vaccine aspiration effects. Oral swabs 
and/or fecal samples were collected from skunks, raccoons, fox, cotton rats, cats and dogs. Viral 
shedding (if any) was generally complete by 4 days post-inoculation (dpi) except for one skunk, 
which continued to shed virus in feces through 14 dpi (Knowles et al. 2009).  
Our research expands on the species evaluated by Knowles et al. (2009) and investigates the 
vaccine as it relates to its safety in wildlife species likely to come in contact with the ONRAB® 
vaccine as part of WS NRMP ORV operations, as well as, identify whether Had5 shed from 
certain wildlife species may increase the chance of humans contacting the Had5.  As expected, 
histological changes described in the non-target species vaccinated with ONRAB® (eastern 
cottontails, fox squirrels, opossums and wild turkeys) are best attributed to common pathologic 
changes in free-ranging wildlife. None of the histological findings in tissues of the study animals 
appear to be related to the ONRAB® vaccine (Table 1). 
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Table 1.  A summary of histological findings unrelated to vaccination by ONRAB® are summarized by species. 
Species n Vaccinates Non-vaccinates 
Cottontail Rabbit (Sylvilagus floridanus) 16 14 2 
Eastern Wild Turkey (Meleagris gallopavo silvestri) 23 21 2 
Virginia Opossum (Didelphis virginiana) 19 17 2 
Fox Squirrel (Sciurus niger) 23 21 2 
 
Cottontail rabbits: The most common finding in the cottontails (n=16), both vaccinates and non-
vaccinates, was the presence of tapeworms in the gastrointestinal tract.  Parasites were observed 
on both gross and histologic examination in 12/16 animals; histologically there was often a very 
mild increase in the number of lymphocytes and plasma cells in the lamina propria of infected 
animals.  In the liver of two vaccinated animals there were areas of inflammation, regionally 
extensive and histiocytic with multinucleated giant cells in one animal and a focal granuloma 
with fibrosis in another animal that was presumed to be secondary to parasite migration.  A 
degenerate parasite was identified within the center of the granuloma.  Very mild, patchy 
interstitial nephritis was observed in two cottontails and lymphoplasmacytic aggregates in portal 
areas of the liver were seen in 5 cottontails, both vaccinates and non-vaccinates.  One cottontail 
had a small focus of inflammation in the lung while another had some mild bronchiole associated 
lymphoid tissue (BALT) hyperplasia.  Findings in the large intestine or spleen of all cottontails 
were unremarkable. Histological variation described for cottontail rabbits are presumably 
unrelated to vaccination with the ONRAB® vaccine. 
Fox Squirrels: The most significant changes in fox squirrels (n=23) were observed in the 
kidneys of both the vaccinated and non-vaccinated animals.  Sixteen fox squirrels, both 
vaccinates and non-vaccinates, had some degree of inflammation in the interstitum of the kidney 
that ranged from mild and patchy to very severe and regionally extensive.  In five animals (4 
vaccinates, 1 non-vaccinate) suppurativetubulitis was also observed, possibly a result of naturally 
acquired leptospirosis infection. In the liver of fourteen fox squirrels, including both vaccinates 
and non-vaccinates, there were small aggregates of lymphocytes and plasma cells in portal areas.  
Mild bronchial associated lymphoid tissue hyperplasia was seen in the lung of 4/23 animals with 
no apparent cause (1 non-vaccinate, 3 vaccinates).  A single fox squirrel had a small focus of 
acute inflammation in the lung.  Mild, patchy increases in lymphocytes and plasma cells were 
seen in the small or large intestine of three fox squirrels (1 non-vaccinate, 2 vaccinates).  
Histological variation described for fox squirrels are presumably unrelated to vaccination with 
the ONRAB® vaccine. 
Opossums: On gross examination of opossums (n=19) multiple metazoan parasites were seen 
throughout the gastrointestinal tracts of nearly all opossums.  Histologically there were numerous 
eosinophils as well as lymphocytes and plasma cells in the small intestine of all opossums 
(vaccinates and non-vaccinates), but fewer inflammatory cells were present in the colon.  On 
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gross examination, the livers of all opossums were mildly enlarged and fatty on palpation.  
Histologically fatty change was seen most commonly in centrilobular areas, but panlobular in 
many animals.  Inflammation similar to that seen in the gastrointestinal tract (eosinophillic to 
mixed infiltrate) was observed in portal areas of the liver of 14 opossums (2 non-vaccinates, 12 
vaccinate) and ranged from very mild to moderate.  Mild interstitial, lymphoplasmacytic 
inflammation was seen in the kidney of 11 opossums (2 non-vaccinates, 9 vaccinates) and 
mineralization was identified in the collecting tubules of 2 (both vaccinates) opossums.  A single 
animal had a moderate amount of interstitial inflammation that also included eosinophils and 
there was some mild, secondary tubular distortion.  Foci of mineralization were identified in the 
lung of 8 animals (2 non-vaccinates, 6 vaccinates).  Mineral was usually devoid of associated 
reaction however foci of inflammation were identified in 10 animals (2 non-vaccinate, 8 
vaccinates).  Inflammatory change ranged from small foci of foamy macrophages and 
lymphocytes, to a single opossum with a mineralized granuloma and a single opossum with a 
large protazoal cyst surrounded with mixed inflammation (non-vaccinate).  Airway associated 
lymphoid tissue was often hyperplastic and contained amyloid.  Histological variation described 
for opossums are presumably unrelated to vaccination with the ONRAB® vaccine. 
Wild Turkeys: The most significant histologic change observed in the wild turkeys (n=23) was a 
variable amount of extramedullaryhematopoesis in multiple tissues.  Change was most notable in 
the liver (2 non-vaccinates, 13 vaccinates) but also present in the intestinal tract and the lung 
(five turkeys, all vaccinates).  Dust granulomas were seen in the lungs of six birds.  Two 
vaccinated turkeys had small foci of heterophillic inflammation in the kidneys and three had 
notable extra medulla hematokinesis.  Histologic changes were uncommon in the gastrointestinal 
tract; extra medulla hematokinesis was variable and a single turkey had a focal, small crypt 
abscess in the gastrointestinal tract. Histological variation described for wild turkeys are 
presumably unrelated to vaccination with the ONRAB® vaccine. 
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